ADMA vs ALGN: fair value comparison
ADMA Biologics, Inc. and Align Technology, Inc. · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ADMA currently sits closer to the top of our discount ranking.
| ADMA | ALGN | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $8.74 | $158.63 |
| 12-month range | $7.90–$19.38 | $137.88–$189.02 |
| Sector rank | #1 of 113 Healthcare | #10 of 113 Healthcare |
| Quality grade | B | B |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | High | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: ADMA fair value analysis · ALGN fair value analysis